login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
BIOGEN INC (BIIB) Stock News
NASDAQ:BIIB - Nasdaq -
US09062X1037
-
Common Stock
- Currency: USD
134.625
-0.56 (-0.42%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BIIB Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Chartmill
- Mentions:
DOW
GE
RJF
PWR
...
Exploring the top movers within the S&P500 index during today's session.
18 hours ago - By: Bragar Eagel & Squire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2 days ago - By: Bloomberg
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs
2 days ago - By: Zacks Investment Research
- Mentions:
CRMD
DNLI
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
3 days ago - By: Biogen Inc.
- Mentions:
STOK
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
3 days ago - By: Stoke Therapeutics, Inc.
- Mentions:
STOK
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
3 days ago - By: Biogen Inc.
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
10 days ago - By: Yahoo Finance
- Mentions:
VZ
Biogen Inc. (BIIB): A Bull Case Theory
13 days ago - By: Benzinga
Beyond The Numbers: 8 Analysts Discuss Biogen Stock
13 days ago - By: Yahoo Finance
- Mentions:
ALLO
REGN
BMY
Regeneron cancer bispecific rejected again; Allogene discloses trial death
14 days ago - By: Yahoo Finance
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
14 days ago - By: Yahoo Finance
Biogen signals Leqembi sales gaining momentum, lifts profit forecast
14 days ago - By: Bloomberg
Biogen Lifts Profit Guidance on Rising Sales of Alzheimer’s Drug
14 days ago - By: Benzinga
- Mentions:
BSAC
BGC
RMNI
MTZ
...
Earnings Scheduled For July 31, 2025
15 days ago - By: Biogen Inc.
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
15 days ago - By: Biogen Inc.
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
15 days ago - By: Eisai Inc.
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
20 days ago - By: Biogen Inc.
- Mentions:
SAGE
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
20 days ago - By: Biogen Inc.
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
20 days ago - By: Bloomberg
- Mentions:
LLY
Lilly Gets Limited European Backing for Alzheimer’s Disease Drug
24 days ago - By: Biogen Inc.
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
24 days ago - By: Biogen Inc.
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Please enable JavaScript to continue using this application.